Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
0.00 | -45.04M | -25.51M | -14.54M | -6.64M | EBITDA |
-22.74M | -45.04M | 0.00 | 0.00 | 0.00 | Net Income Common Stockholders |
-24.59B | -56.20M | -25.15M | -14.44M | -4.26M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
10.55M | 5.75M | 28.38M | 45.69M | 8.07M | Total Assets |
13.93M | 10.21M | 36.02M | 46.00M | 8.12M | Total Debt |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
-10.55M | -5.75M | -28.38M | -45.69M | -8.07M | Total Liabilities |
4.62M | 17.96M | 7.70M | 1.51M | 578.38K | Stockholders Equity |
9.31B | -7.75M | 28.32M | 44.49M | 7.54M |
Cash Flow | Free Cash Flow | |||
-21.89B | -39.97M | -17.31M | -9.13M | -3.97M | Operating Cash Flow |
-21.89B | -39.97M | -17.31M | -9.13M | -3.97M | Investing Cash Flow |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
26.69B | 17.34M | 4.61K | 46.74M | 12.04M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.03 | -44.09% | 2.83% | 16.75% | -0.06% | |
41 Neutral | $28.33M | ― | -853.05% | ― | ― | 34.97% | |
39 Underperform | $24.81M | ― | -70.06% | ― | 146.47% | 57.85% | |
38 Underperform | $28.30M | ― | 78.50% | ― | ― | 55.52% | |
35 Underperform | $22.78M | ― | -246.21% | ― | ― | 44.38% | |
35 Underperform | $38.58M | ― | -280.78% | ― | ― | 68.75% | |
$36.58M | ― | -197.22% | ― | ― | ― |
On March 26, 2025, Annovis Bio, Inc. received a notice from the New York Stock Exchange (NYSE) indicating non-compliance with the NYSE’s continued listing standards due to its average market capitalization and stockholders’ equity falling below $50 million. The company plans to submit a compliance plan within 45 days, which the NYSE will review to determine if Annovis can meet the standards within an 18-month period. The notice does not affect the company’s business operations or its reporting obligations, and its stock will continue to be traded with a ‘.BC’ designation until compliance is regained.
On February 5, 2025, Annovis Bio Inc. announced the commencement of its pivotal Phase 3 study for the drug buntanetap in early Alzheimer’s disease, marking a significant step toward market approval. The study, which follows promising results from previous trials, is designed to assess both symptomatic and potential disease-modifying effects over an 18-month period and involves over 750 participants across the United States.